EBUS-TBNA细胞学在肺癌纵隔淋巴结分期中的关键作用:与PET表现的相关性研究
回顾约翰霍普金斯医疗机构14个月内同时接受EBUS-TBNA纵隔淋巴结采样与PET扫描的肺癌疑似或既往肺癌患者,共纳入79例患者的140枚淋巴结(PET阳性86枚、阴性54枚),比较细胞学诊断与PET结果。PET阳性淋巴结中41.9%为恶性,而PET阴性淋巴结中仍有7.4%为恶性,提示单用PET存在假阴性风险。
要点
- PET阳性淋巴结中仅41.9%经EBUS-TBNA证实为恶性,需组织采样确认。
- PET阴性淋巴结中7.4%经EBUS-TBNA检出恶性,单用PET有假阴性风险。
- EBUS-TBNA细胞学可提高纵隔淋巴结诊断准确性并改善临床分期。
核心结论
- EBUS-TBNA细胞学提高纵隔淋巴结诊断准确性与临床分期,并可检出PET阴性的额外恶性淋巴结(7.4%),提示单用PET扫描存在假阴性风险。
研究设计与样本
- 回顾性检索约翰霍普金斯医疗机构电子数据库与病理档案,纳入14个月内同时行EBUS-TBNA纵隔淋巴结采样和PET扫描的纵隔淋巴结病患者,包括疑似肺癌及有肺癌病史者。
- 共纳入79例患者的140枚淋巴结,其中PET阳性86枚、PET阴性54枚;复习细胞学诊断与后续手术淋巴结诊断,并与PET结果对照。
主要发现
- PET阳性淋巴结中41.9%为恶性,41.9%为反应性改变或肉芽肿性炎症,9.3%为EBUS-TBNA非诊断性。
- PET阴性淋巴结中74.1%为反应性改变或肉芽肿性炎症,7.4%为恶性,18.5%为EBUS-TBNA非诊断性。
- 采样最多的淋巴结为4R和7。
- PET阳性与PET阴性淋巴结的平均大小分别为1.2 cm和1.6 cm。
临床怎么用
- 对PET阳性纵隔淋巴结应行EBUS-TBNA组织采样确认,因其中约四成为良性反应性改变或肉芽肿性炎症。
- 对PET阴性纵隔淋巴结亦不应完全排除恶性,EBUS-TBNA可检出约7.4%的额外恶性淋巴结以完善分期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The sensitivity and specificity of positron emission tomography (PET) have been significantly improved for the identification of malignancies in recent years; however, it is still necessary to confirm PET findings in a lymph node (LN) by direct tissue sampling. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is the most commonly used approach for diagnosing and staging mediastinal LNs, particularly in lung cancer patients with locally advanced disease. Despite this fact, evidence-based studies of EBUS-TBNA cytology and PET findings are still suboptimal. METHODS: The electronic database at the Johns Hopkins Medical Institutions and the pathology archives were searched to identify patients with mediastinal lymphadenopathy who had both EBUS-TBNA mediastinal LN sampling and a PET scan over a 14-month period. Patients suspected of having lung cancer and patients with a history of lung cancer were included in this study. Cytological diagnoses and follow-up surgical LN diagnoses were reviewed and correlated with PET scan findings. RESULTS: A total of 140 LNs from 79 patients, including 86 PET-positive LNs and 54 PET-negative LNs, were included. The most frequently sampled LNs were 4R and 7. The average size of PET-positive and PET-negative LNs was 1.2 and 1.6 cm, respectively. Among PET-positive LNs, 41.9% were malignant, 41.9% showed reactive changes or granulomatous inflammation, and 9.3% were nondiagnostic by EBUS-TBNA. However, among PET-negative LNs, 74.1% showed reactive changes or granulomatous inflammation, 7.4% were malignant, and 18.5% were nondiagnostic by EBUS-TBNA. CONCLUSIONS: The data demonstrate that EBUS-TBNA cytology improves the diagnostic accuracy of mediastinal LNs and clinical staging. Furthermore, EBUS-TBNA may identify additional malignant LNs (7.4%), and this highlights the risk for false-negative findings with PET scanning in isolation. Cancer Cytopathol 2017;125:717-25. © 2017 American Cancer Society.
引用
- Lilo MT, Allison DB, Younes BK, et al. The critical role of EBUS-TBNA cytology in the staging of mediastinal lymph nodes in lung cancer patients: A correlation study with positron emission tomography findings. Cancer Cytopathol. 2017. PMID: 28609021. doi:10.1002/cncy.21886
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。